Contribution of the seric cytokeartin fragment 21.1 (cyf 21.1) as a tumor marker in a population of algerien women with breast cancer undergoing chemotherapy

##plugins.themes.academic_pro.article.sidebar##

Published Feb 15, 2026
https://doi.org/10.62438/tunismed.v103i12.5746
Download
PDF
Vol. 103 No. 12 (2025): Tunis Med Dec 2025

##plugins.themes.academic_pro.article.main##

Zohra Sedoud
Central laboratory, Biochemistry laboratory, Rouiba hospital,16012, Faculty of pharmacy of algiers, University of Algiers 1, Algiers, 16028, Algeria .
Yousra Hellal
Central laboratory, Biochemistry laboratory, Rouiba hospital,16012, Faculty of pharmacy of algiers, University of Algiers 1, Algiers, 16028, Algeria .
Racha Benafla
Central laboratory, Biochemistry laboratory, Rouiba hospital,16012, Faculty of pharmacy of algiers, University of Algiers 1, Algiers, 16028, Algeria .
Sabrine Deghima
Central laboratory, Biochemistry laboratory, Rouiba hospital,16012, Faculty of pharmacy of algiers, University of Algiers 1, Algiers, 16028, Algeria .
Kamel Djenouhat
Central laboratory, Biochemistry laboratory, Rouiba hospital,16012, Faculty of pharmacy of algiers, University of Algiers 1, Algiers, 16028, Algeria .

Abstract

: In Algeria, breast cancer accounts for 37.8% of new cancer cases in women. It is an epithelial cell tumor in most cases. CA15-3 (carbohydrate antigen) is the marker of choice for therapeutic monitoring, although ASCO (the American Society of Clinical Oncology) does not recommend its routine use, preferring CYFRA21.1 (cytokeratin19 fragment) to assess response to treatment. The aim of this study was to estimate the degree of correlation between these two biological markers as a function of tumour histological type and the presence or absence of metastases. In a prospective descriptive study, sera from 110 breast cancer patients (mean age 49 ± 7.23 years) were measured using the electrochemiluminescence (ECL) technique to assess CYFRA 21.1 and CA 15.3 levels. Comparison of CA15.3 and CYFRA21.1 levels between patients and controls (79 controls) showed a highly significant association (p<0.0001) between these two markers and breast cancer. The significant correlation between CA15.3 and CYFRA21.1 (r=0.245; P< 0.0001) suggests that reliance on CYF 21.1 for monitoring breast cancer patients undergoing chemotherapy is possible. The results show a good correlation between the two markers, especially for the two histological types luminal a and luminal b+HER2 (r=0.602 ; p<0.0001, r=0.505 ;p< 0.0001 respectively). This study also assessed the correlation between CA15.3 and CYFRA21.1 levels in patients with and without metastases. A significant correlation was also found between CA15.3 and CYFRA 21.1 in the presence of metastases (r=0.472, p<0.0001). A multi-marker approach could provide a more comprehensive assessment of tumor burden and response to treatment.

Keywords:

breast cancer, CA15.3(carbohydrate antigen), CYFRA21.1(cytokeratin19 fragment), therapeutic monitoring

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Hammouda PD. ALGER TUMOR REGISTRY.
  2. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. nov 2022;72(6):524 41.
  3. Nath S, Mukherjee P. Muc1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. June 2014;20(6):332-42.
  4. De La Lande B. Current place of CA 15.3 assays in breast cancer. Immuno-Anal Biol Spéc. oct 2004;19(5):274 8.
  5. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 27 Jul. 2004;91(5):873.
  6. Masson D, Le Boterff C, Lacroix H, Denis M, Dabouis G, Lustenberger P, et al. Anti-p53 autoantibodies and serum markers, NSE and CYFRA 21-1, in bronchopulmonary cancers. Immuno-Anal Biol Spéc. janv 2001;16(1):28 33.
  7. Molina R, Agusti C, Filella X, Jo J, Joseph J, Giménez N, et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 1994;15(6):318-25.
  8. Stieber P, Bodenmüller H, Banauch D, Hasholzner U, Dessauer A, Ofenloch-Hähnle B, et al. Cytokeratin 19 fragments: A new marker for non-small-cell lung cancer. Clin Biochem. August 1993;26(4):301-4.
  9. Rodríguez CA, Cruz JJ, Martín T, Gómez A, Olaverri A, Hernández M. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer. August 2002;95(3):670-1.
  10. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, et al. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer. 15 Sep 2000;89(6):1285-90.
  11. Brotherick I, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ, et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry. August 1, 1998;32(4):301-8.
  12. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S. Serum Cytokeratin Fragment 21.1 (CYFRA 21.1) as Tumour Marker for Breast Cancer: Comparison with Carbohydrate Antigen 15.3 (CA 15.3) and Carcinoembryonic Antigen (CEA). Clin Chem Lab Med [Internet]. 2002 Jan 10 [cited 2024 Nov 25];40(3). Available from: https://www.degruyter.com/document/doi/10.1515/CCLM.2002.047/html
  13. Mesa-Tejada R, Palakodety RB, Leon JA, Khatcherian AO, Greaton CJ. Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. Am J Pathol. Feb 1988;130(2):305 14.
  14. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat. Sept 1998;51(2):109-19.
  15. Nemoto T, Constantine R, Chu TM. Human tissue polypeptide antigen in breast cancer. J Natl Cancer Inst. dec 1979;63(6):1347 50.
  16. Bray KR, Koda JE, Gaur PK. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res. 15 nov 1987;47(22):5853 60.